Randomized Blinded Phase II Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Sunitinib (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 12 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 10 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Sep 2010 Planned end date changed from 1 Jan 2010 to 1 Jun 2015 as reported by ClinicalTrials.gov.